- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 10-K Annual report
- 3.1 Certificate of Incorporation
- 10.13 Form of Incentive Stock Option Agreement
- 10.14 Form of Nonqualified Stock Option Agreement for Grants to Employees
- 10.15 Form of Nonqualified Stock Option Agreement for Grants to Directors
- 10.30 Separation Agreement and General Release
- 10.31 Consulting and Confidentiality Agreement
- 10.38 Employment Agreement
- 10.41 Agreement and Release
- 10.42 Fourth Amendment to Employment and Confidential Information Agreement
- 10.48 Amendment, Dated January 8, 2010, to the Asset Purchase Agreement
- 21 List of Subsidiaries
- 23.1 Consent of KPMG LLP
- 31.1 Certification of Chief Executive Officer Pursuant to Rule 13A-14(A)
- 31.2 Certification of Chief Financial Officer Pursuant to Rule 13A-14(A)
- 32.1 Certification of Chief Executive Officer Pursuant to 18 U.s.c. Section 1350
- 32.2 Certification of Chief Financial Officer Pursuant to 18 U.s.c. Section 1350
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of K-V Pharmaceutical Company (the “Company”) on Form 10-K for the fiscal year ended March 31, 2009, as filed with the Securities and Exchange Commission (the “Report”), I, David A. Van Vliet, Interim President and Interim Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: March 25, 2010 | /s/ David A. Van Vliet | |||||
David A. Van Vliet Interim President and Interim Chief Executive Officer |
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
The foregoing certification is being furnished to the Securities and Exchange Commission as our exhibit to the Form 10-K and shall not be deemed to be considered filed as part of the Form 10-K.